Who are MMF and Dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Systemic corticosteroids/methotrexate, Mycophenolate to sirolimus switch, LCP-tacrolimus QD + MMF QD then MMF QD, Tacrolimus/MMF, XR-tacrolimus QD + MMF BID, MMF (Cellcept) and Steroids.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mmf-and-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MMF and Dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MMF and Dexamethasone (MMF and Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant combination. Area: Immunology.

phase 3 Immunosuppressant combination IMPDH (mycophenolate); glucocorticoid receptor (dexamethasone) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

MMF and Dexamethasone (MMF and Dexamethasone) — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). MMF (mycophenolate mofetil) suppresses T and B cell proliferation while dexamethasone provides broad immunosuppression and anti-inflammatory effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MMF and Dexamethasone TARGET	MMF and Dexamethasone	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	phase 3	Immunosuppressant combination	IMPDH (mycophenolate); glucocorticoid receptor (dexamethasone)
Systemic corticosteroids/methotrexate	Systemic corticosteroids/methotrexate	Merck KGaA, Darmstadt, Germany	marketed	Immunosuppressant combination (corticosteroid + DMARD)	Glucocorticoid receptor (corticosteroids); dihydrofolate reductase (methotrexate)
Mycophenolate to sirolimus switch	Mycophenolate to sirolimus switch	London Health Sciences Centre	marketed	Immunosuppressant combination therapy	mTOR (sirolimus component); IMPDH (mycophenolate component being replaced)
LCP-tacrolimus QD + MMF QD then MMF QD	LCP-tacrolimus QD + MMF QD then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF)
Tacrolimus/MMF	Tacrolimus/MMF	University of Miami	marketed	Immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (MMF)
XR-tacrolimus QD + MMF BID	XR-tacrolimus QD + MMF BID	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
MMF (Cellcept) and Steroids	MMF (Cellcept) and Steroids	University of Luebeck	marketed	Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid)	IMPDH type II; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant combination class)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
St. Anne's University Hospital Brno, Czech Republic · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University of Giessen · 1 drug in this class
University of Miami · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MMF and Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/mmf-and-dexamethasone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing